[go: up one dir, main page]

DK1915620T3 - Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer - Google Patents

Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer

Info

Publication number
DK1915620T3
DK1915620T3 DK06795161.6T DK06795161T DK1915620T3 DK 1915620 T3 DK1915620 T3 DK 1915620T3 DK 06795161 T DK06795161 T DK 06795161T DK 1915620 T3 DK1915620 T3 DK 1915620T3
Authority
DK
Denmark
Prior art keywords
autoantibodies
vascular diseases
1alpha
contraception
diagnosis
Prior art date
Application number
DK06795161.6T
Other languages
English (en)
Inventor
John Simard
Klaus Bendtzen
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Application granted granted Critical
Publication of DK1915620T3 publication Critical patent/DK1915620T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK06795161.6T 2005-08-02 2006-07-26 Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer DK1915620T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70445005P 2005-08-02 2005-08-02
PCT/IB2006/002038 WO2007015128A1 (en) 2005-08-02 2006-07-26 DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES

Publications (1)

Publication Number Publication Date
DK1915620T3 true DK1915620T3 (da) 2010-10-04

Family

ID=37442093

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06795161.6T DK1915620T3 (da) 2005-08-02 2006-07-26 Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer

Country Status (11)

Country Link
US (2) US8187817B2 (da)
EP (2) EP1915620B1 (da)
JP (2) JP5645361B2 (da)
CN (2) CN101253409A (da)
AT (1) ATE470151T1 (da)
AU (1) AU2006274698B2 (da)
CA (1) CA2617637C (da)
DE (1) DE602006014691D1 (da)
DK (1) DK1915620T3 (da)
ES (1) ES2346691T3 (da)
WO (1) WO2007015128A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253409A (zh) * 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ATE551365T1 (de) 2006-05-15 2012-04-15 Xbiotech Inc Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques.
WO2007135546A2 (en) * 2006-05-22 2007-11-29 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
MX2010012963A (es) 2008-05-30 2011-04-05 Xbiotech Inc Anticuerpos de interleucina-1 alfa y metodos de uso.
US8242074B2 (en) * 2008-09-12 2012-08-14 Xbiotech, Inc. Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
EP2569640A1 (en) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
KR102314003B1 (ko) 2010-08-23 2021-10-19 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
WO2012067165A1 (ja) * 2010-11-17 2012-05-24 国立大学法人愛媛大学 自己免疫疾患に関与するタンパク質の解析方法及び該疾患の検査方法
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127A (zh) 2011-09-23 2018-08-17 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
EP3761991A4 (en) * 2018-03-09 2022-01-12 The Brigham and Women's Hospital, Inc. COMBINATION THERAPY FOR CARDIOVASCULAR DISEASES
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
KR20220019674A (ko) * 2019-05-03 2022-02-17 유니베르시태트 취리히 뇌 허혈-재관류 손상의 치료

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) * 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU5355094A (en) * 1992-10-14 1994-05-09 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
ES2159529T5 (es) * 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20040048274A1 (en) * 2000-10-17 2004-03-11 Morten Breindahl Assay for directly detecting an inflammatory indicator in a body fluid sample
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
SI1572946T1 (sl) * 2002-09-06 2012-09-28 Amgen Inc Terapevtsko humano anti-il-1r1 monoklonsko protitelo
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
SG158119A1 (en) 2004-12-09 2010-01-29 Centocor Inc Anti-integrin immunoconjugates, methods and uses
CN101253409A (zh) * 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ATE551365T1 (de) * 2006-05-15 2012-04-15 Xbiotech Inc Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques.
WO2007135546A2 (en) * 2006-05-22 2007-11-29 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
BRPI0711249A2 (pt) * 2006-05-30 2012-03-13 Genentech, Inc. Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
JP2011521896A (ja) 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
MX2010012963A (es) * 2008-05-30 2011-04-05 Xbiotech Inc Anticuerpos de interleucina-1 alfa y metodos de uso.
US8242074B2 (en) * 2008-09-12 2012-08-14 Xbiotech, Inc. Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
NZ593905A (en) 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins

Also Published As

Publication number Publication date
DE602006014691D1 (de) 2010-07-15
EP1915620A1 (en) 2008-04-30
US8865175B2 (en) 2014-10-21
CA2617637C (en) 2017-07-18
US20120231012A1 (en) 2012-09-13
CN101253409A (zh) 2008-08-27
AU2006274698B2 (en) 2011-06-09
JP5645361B2 (ja) 2014-12-24
AU2006274698A2 (en) 2008-03-06
EP1915620B1 (en) 2010-06-02
EP2216653A1 (en) 2010-08-11
JP5717256B2 (ja) 2015-05-13
JP2013127469A (ja) 2013-06-27
ATE470151T1 (de) 2010-06-15
AU2006274698A1 (en) 2007-02-08
ES2346691T3 (es) 2010-10-19
JP2009503529A (ja) 2009-01-29
US8187817B2 (en) 2012-05-29
WO2007015128A1 (en) 2007-02-08
CN109187944A (zh) 2019-01-11
US20090123415A1 (en) 2009-05-14
CA2617637A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
CY2023004I2 (el) Συνθεσεις irna τρανσθυρετινης (ttr) και μεθοδοι χρησεως αυτων για τη θεραπευτικη αγωγη ή προληψη σχετιζομενων me ttr ασθενειων
BRPI0814339A2 (pt) composição farmacêutica, kit para a preparação da composição farmacêutica, conjugado, e, métodos de formação de imagem óptica in vivo do corpo de mamíferos, e de detecção, estabilização, diagnóstico, monitoramento do progresso da doença ou monitoramento do tratamento de um estado doentio do corpon dos mamíferos
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
LTPA2016034I1 (lt) Brutono tirozinkinazės inhibitoriai
EA200802204A1 (ru) Применение ингибиторов dpp iv
EP1851237A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EA200870325A1 (ru) Лекарственные формы для введения комбинаций лекарственных средств
NO20073816L (no) Kombinasjonsterapi for behandling av diabetes og tilstander relatert dertil og for behandling av tilstanden som er bedret ved a oke blod GLP-1 nivaet
BRPI0717697A2 (pt) composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CO6390078A2 (es) Inihibidores de syk de imidazopirazina
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
BRPI0821895A2 (pt) Composiçao farmacêutica, método de tratamento ou prevenção de uma doença, uma condição e sintomas das mesmas em animais de sangue quente, incluindo seres humanos, método de preparação da composição farmacêutica e método para diagnosticar uma doença, condição, síndrome.
BRPI0717741A2 (pt) Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
NO20076405L (no) Anvendelse av 24-nor-UDCA
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
BRPI0607851A2 (pt) compostos e usos dos mesmos
DK1778837T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer
FR2864903B1 (fr) Appareil de traitement notamment par laser d'un cancer ou d'un etat precancereux
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds